TY - JOUR
T1 - Antibody response, associated symptoms and profile of patients presumably infected by SARS-CoV-2 with taste or smell disorders in the SAPRIS multicohort study
AU - the SAPRIS-SERO study group
AU - the SAPRIS study group
AU - Ramillon, Julien
AU - de Lamballerie, Xavier
AU - Robineau, Olivier
AU - Blanché, Hélène
AU - Severi, Gianluca
AU - Touvier, Mathilde
AU - Zins, Marie
AU - Carrat, Fabrice
AU - Ancel, Pierre Yves
AU - Charles, Marie Aline
AU - Kab, Sofiane
AU - Renuy, Adeline
AU - Le-Got, Stéphane
AU - Ribet, Céline
AU - Wiernik, Emmanuel
AU - Goldberg, Marcel
AU - Artaud, Fanny
AU - Gerbouin-Rérolle, Pascale
AU - Enguix, Melody
AU - Laplanche, Camille
AU - Gomes-Rima, Roselyn
AU - Hoang, Lyan
AU - Correia, Emmanuelle
AU - Barry, Alpha Amadou
AU - Senina, Nadège
AU - Szabo de Edelenyi, Fabien
AU - Druesne-Pecollo, Nathalie
AU - Esseddik, Younes
AU - Hercberg, Serge
AU - Benhammou, Valérie
AU - Ritmi, Anass
AU - Marchand, Laetitia
AU - Zaros, Cécile
AU - Lordmi, Elodie
AU - Candea, Adriana
AU - de Visme, Sophie
AU - Simeon, Thierry
AU - Thierry, Xavier
AU - Geay, Bertrand
AU - Dufourg, Marie Noëlle
AU - Milcent, Karen
AU - Lusivika-Nzinga, Clovis
AU - Pannetier, Gregory
AU - Lapidus, Nathanael
AU - Goderel, Isabelle
AU - Dorival, Céline
AU - Nicol, Jérôme
AU - Lai, Cindy
AU - Esperou, Hélène
AU - Couffin-Cadiergues, Sandrine
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12/1
Y1 - 2023/12/1
N2 - Background: Taste or smell disorders have been reported as strongly associated with COVID-19 diagnosis. We aimed to identify subject characteristics, symptom associations, and antibody response intensity associated with taste or smell disorders. Methods: We used data from SAPRIS, a study based on a consortium of five prospective cohorts gathering 279,478 participants in the French general population. In the analysis, we selected participants who were presumably infected by SARS-CoV-2 during the first epidemic wave. Results: The analysis included 3,439 patients with a positive ELISA-Spike. Sex (OR = 1.28 [95% CI 1.05–1.58] for women), smoking (OR = 1.54 [95% CI 1.13–2.07]), consumption of more than 2 drinks of alcohol a day (OR = 1.37 [95% CI 1.06–1.76]) were associated with a higher probability of taste or smell disorders. The relationship between age and taste or smell disorders was non-linear. Serological titers were associated with taste or smell disorders: OR = 1.31 [95% CI 1.26–1.36], OR = 1.37 [95% CI 1.33–1.42] and OR = 1.34 [95% CI 1.29–1.39] for ELISA-Spike, ELISA-Nucleocapsid and seroneutralization, respectively. Among participants with taste or smell disorders, 90% reported a wide variety of other symptoms whereas 10% reported no other symptom or only rhinorrhea. Conclusions: Among patients with a positive ELISA-Spike test, women, smokers and people drinking more than 2 drinks a day were more likely to develop taste or smell disorders. This symptom was strongly associated with an antibody response. The overwhelming majority of patients with taste or smell disorders experienced a wide variety of symptoms.
AB - Background: Taste or smell disorders have been reported as strongly associated with COVID-19 diagnosis. We aimed to identify subject characteristics, symptom associations, and antibody response intensity associated with taste or smell disorders. Methods: We used data from SAPRIS, a study based on a consortium of five prospective cohorts gathering 279,478 participants in the French general population. In the analysis, we selected participants who were presumably infected by SARS-CoV-2 during the first epidemic wave. Results: The analysis included 3,439 patients with a positive ELISA-Spike. Sex (OR = 1.28 [95% CI 1.05–1.58] for women), smoking (OR = 1.54 [95% CI 1.13–2.07]), consumption of more than 2 drinks of alcohol a day (OR = 1.37 [95% CI 1.06–1.76]) were associated with a higher probability of taste or smell disorders. The relationship between age and taste or smell disorders was non-linear. Serological titers were associated with taste or smell disorders: OR = 1.31 [95% CI 1.26–1.36], OR = 1.37 [95% CI 1.33–1.42] and OR = 1.34 [95% CI 1.29–1.39] for ELISA-Spike, ELISA-Nucleocapsid and seroneutralization, respectively. Among participants with taste or smell disorders, 90% reported a wide variety of other symptoms whereas 10% reported no other symptom or only rhinorrhea. Conclusions: Among patients with a positive ELISA-Spike test, women, smokers and people drinking more than 2 drinks a day were more likely to develop taste or smell disorders. This symptom was strongly associated with an antibody response. The overwhelming majority of patients with taste or smell disorders experienced a wide variety of symptoms.
KW - COVID-19 serological testing
KW - General population
KW - SARS-CoV-2
KW - Smell disorders
KW - Taste disorders
UR - http://www.scopus.com/inward/record.url?scp=85152543835&partnerID=8YFLogxK
U2 - 10.1186/s12879-023-08162-7
DO - 10.1186/s12879-023-08162-7
M3 - Article
C2 - 37060075
AN - SCOPUS:85152543835
SN - 1471-2334
VL - 23
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
IS - 1
M1 - 228
ER -